Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA expanded the approval of the bivalent ...

While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...

Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults aged over 18 years.

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...

Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.

A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival ...

The US Food and Drug Administration (FDA) yesterday approved Abrysvo (respiratory syncytial virus vaccine). Developed and ...

Pfizer's RSV vaccine Abrysvo receives FDA approval for adults 18-59 at high risk, with extended use for pregnant individuals ...

The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO® (Respiratory ...

The approval for the vaccine, Abrysvo, in adults aged 18 to 59 was based on the results from a late stage trial in which two ...

The RSV vaccine Abrysvo was highly effective against hospital and ED encounters in a large cohort of older adults with comorbidities and immunocompromising conditions.